Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

H Hjorth-Hansen, J Stentoft, J Richter, P Koskenvesa, M Höglund, A Dreimane, K Porkka, T Gedde-Dahl, B T Gjertsen, F X Gruber, L Stenke, K M Eriksson, B Markevärn, A Lübking, H Vestergaard, L Udby, O W Bjerrum, I Persson, S Mustjoki, U Olsson-Strömberg

    59 Citationer (Scopus)

    Abstract

    Dasatinib (DAS) and interferon-α have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-α2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 μg/week and it increased to 25 μg/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR(4) was achieved by 46% and MR(4.5) by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS±PegIFN is warranted.

    OriginalsprogEngelsk
    TidsskriftLeukemia
    Vol/bind30
    Udgave nummer9
    Sider (fra-til)1853-60
    Antal sider8
    ISSN0887-6924
    DOI
    StatusUdgivet - sep. 2016

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients'. Sammen danner de et unikt fingeraftryk.

    Citationsformater